Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $47

Benzinga · 3d ago
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target from $55 to $47.